MEDIPOST (Korea) Performance
| 078160 Stock | KRW 12,350 380.00 3.17% |
MEDIPOST holds a performance score of 16 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 0.18, which conveys not very significant fluctuations relative to the market. As returns on the market increase, MEDIPOST's returns are expected to increase less than the market. However, during the bear market, the loss of holding MEDIPOST is expected to be smaller as well. Use MEDIPOST downside deviation, standard deviation, and the relationship between the semi deviation and coefficient of variation , to analyze future returns on MEDIPOST.
Risk-Adjusted Performance
16 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in MEDIPOST Co are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, MEDIPOST sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | -8.2 B |
MEDIPOST |
MEDIPOST Relative Risk vs. Return Landscape
If you would invest 594,000 in MEDIPOST Co on September 22, 2024 and sell it today you would earn a total of 641,000 from holding MEDIPOST Co or generate 107.91% return on investment over 90 days. MEDIPOST Co is generating 1.3834% of daily returns and assumes 6.4785% volatility on return distribution over the 90 days horizon. Simply put, 57% of stocks are less volatile than MEDIPOST, and 73% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
MEDIPOST Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MEDIPOST's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MEDIPOST Co, and traders can use it to determine the average amount a MEDIPOST's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2135
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | 078160 | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.48 actual daily | 57 57% of assets are less volatile |
Expected Return
| 1.38 actual daily | 27 73% of assets have higher returns |
Risk-Adjusted Return
| 0.21 actual daily | 16 84% of assets perform better |
Based on monthly moving average MEDIPOST is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MEDIPOST by adding it to a well-diversified portfolio.
MEDIPOST Fundamentals Growth
MEDIPOST Stock prices reflect investors' perceptions of the future prospects and financial health of MEDIPOST, and MEDIPOST fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MEDIPOST Stock performance.
| Return On Equity | 1.87 | |||
| Return On Asset | -0.0113 | |||
| Profit Margin | (0.10) % | |||
| Operating Margin | (0.07) % | |||
| Current Valuation | 453 B | |||
| Shares Outstanding | 15.38 M | |||
| Price To Earning | 9,636 X | |||
| Price To Sales | 4.23 X | |||
| Revenue | 54.86 B | |||
| EBITDA | 583.03 M | |||
| Cash And Equivalents | 9.72 B | |||
| Total Debt | 1.23 B | |||
| Debt To Equity | 0.35 % | |||
| Book Value Per Share | 19,151 X | |||
| Cash Flow From Operations | 4.06 B | |||
| Total Asset | 254.09 B | |||
| Retained Earnings | 14.22 B | |||
| Current Asset | 42.53 B | |||
| Current Liabilities | 18.54 B | |||
About MEDIPOST Performance
By analyzing MEDIPOST's fundamental ratios, stakeholders can gain valuable insights into MEDIPOST's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if MEDIPOST has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MEDIPOST has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. MEDIPOST Co., Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea. MEDIPOST is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about MEDIPOST performance evaluation
Checking the ongoing alerts about MEDIPOST for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MEDIPOST help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MEDIPOST is way too risky over 90 days horizon | |
| MEDIPOST appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 54.86 B. Net Loss for the year was (966.42 M) with profit before overhead, payroll, taxes, and interest of 30.89 B. |
- Analyzing MEDIPOST's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MEDIPOST's stock is overvalued or undervalued compared to its peers.
- Examining MEDIPOST's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MEDIPOST's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MEDIPOST's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MEDIPOST's stock. These opinions can provide insight into MEDIPOST's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for MEDIPOST Stock analysis
When running MEDIPOST's price analysis, check to measure MEDIPOST's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEDIPOST is operating at the current time. Most of MEDIPOST's value examination focuses on studying past and present price action to predict the probability of MEDIPOST's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEDIPOST's price. Additionally, you may evaluate how the addition of MEDIPOST to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| CEOs Directory Screen CEOs from public companies around the world |